There is evidence that inflammatory processes may play a key role during surgical myocardial reperfusion. The hypothesis of this study is that colchicine, an anti-inflammatory agent, may lead to reduction in periprocedural infarct size, when administered during elective coronary artery bypass graft surgery.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* The study will enroll patients 18 years old or older who are eligible to undergo CABG surgery.
Exclusion Criteria:
Excluded are patients:
* with age \> 80 years old
* scheduled for concomitant valve surgery
* scheduled for coronary surgery without cardiopulmonary bypass
* with peripheral vascular disease affecting the upper limbs
* with acute coronary syndrome within the previous 4 weeks
* on inotropic or mechanical circulatory support before induction of anaesthesia
* with any disorder that could potentially increase preoperative cTnI concentrations (eg, percutaneous coronary intervention within the previous 6 weeks)
* with active inflammatory diseases, infectious diseases or known malignancy
* under treatment with corticosteroids, anti-inflammatory agents or disease modifying agents
* with known hypersensitivity-allergy to colchicine
* under chronic treatment with colchicine
* with severe renal failure (eGFR \< 35 ml/min/1.73 m2)
* with hepatic failure (Child - Pugh class B or C)